Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Kieran F. Docherty, Paul Welsh, Subodh Verma, et al.
Circulation (2022) Vol. 146, Iss. 13, pp. 980-994
Open Access | Times Cited: 95

Showing 1-25 of 95 citing articles:

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial
Paul R. Kalra, John G.F. Cleland, Mark C. Petrie, et al.
The Lancet (2022) Vol. 400, Iss. 10369, pp. 2199-2209
Open Access | Times Cited: 256
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
Milton Packer
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 443-462
Open Access | Times Cited: 102
Redefining Iron Deficiency in Patients With Chronic Heart Failure
Milton Packer, Stefan D. Anker, Javed Butler, et al.
Circulation (2024) Vol. 150, Iss. 2, pp. 151-161
Open Access | Times Cited: 17
Rationale and design of the FAIR‐HF2‐DZHK05 trial: Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure
Stefan D. Anker, Tim Friede, Javed Butler, et al.
European Journal of Heart Failure (2025)
Open Access | Times Cited: 3
Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure
Milton Packer
JACC Heart Failure (2022) Vol. 11, Iss. 1, pp. 106-114
Open Access | Times Cited: 50
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial
Camilla Fuchs Andersen, Massar Omar, Andreas Glenthøj, et al.
European Journal of Heart Failure (2022) Vol. 25, Iss. 2, pp. 226-234
Open Access | Times Cited: 48
How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failure
Milton Packer
European Journal of Heart Failure (2022) Vol. 24, Iss. 12, pp. 2287-2296
Open Access | Times Cited: 47
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 38
Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors
Milton Packer
European Heart Journal (2023) Vol. 44, Iss. 48, pp. 5027-5035
Open Access | Times Cited: 36
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease
Akihiko Koshino, Meir Schechter, Glenn M. Chertow, et al.
NEJM Evidence (2023) Vol. 2, Iss. 6
Open Access | Times Cited: 34
Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of America
Craig J. Beavers, Andrew P. Ambrosy, Javed Butler, et al.
Journal of Cardiac Failure (2023) Vol. 29, Iss. 7, pp. 1059-1077
Closed Access | Times Cited: 33
Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure
Christiane E. Angermann, Carlos G. Santos‐Gallego, Juan Antonio Requena-Ibáñez, et al.
Nature Cardiovascular Research (2023) Vol. 2, Iss. 11, pp. 1032-1043
Open Access | Times Cited: 29
Nutrition in chronic inflammatory conditions: Bypassing the mucosal block for micronutrients
Franziska Roth‐Walter, Roberto Berni Canani, Liam O’Mahony, et al.
Allergy (2023) Vol. 79, Iss. 2, pp. 353-383
Open Access | Times Cited: 23
Iron deficiency and supplementation in heart failure
Samira Lakhal‐Littleton, John G.F. Cleland
Nature Reviews Cardiology (2024) Vol. 21, Iss. 7, pp. 463-486
Closed Access | Times Cited: 13
Iron Status and Risk of Heart Disease, Stroke, and Diabetes: A Mendelian Randomization Study in European Adults
Yunan Liu, Robert Clarke, Derrick Bennett, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 6
Open Access | Times Cited: 11
Intravenous iron and SGLT2 inhibitors in iron‐deficient patients with heart failure and reduced ejection fraction
Kieran F. Docherty, John J.V. McMurray, Paul R. Kalra, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 4, pp. 1875-1879
Open Access | Times Cited: 10
Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure
Shodai Kawanami, Yasuyuki Egami, Masaru Abe, et al.
ESC Heart Failure (2025)
Open Access | Times Cited: 1
The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials
Dongmei Wang, J. Y. Liu, Ling Zhong, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 30
Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction
Mingming Yang, Toru Kondo, Carly Adamson, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 9, pp. 1606-1618
Open Access | Times Cited: 20
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia
Milton Packer
American Journal of Nephrology (2023) Vol. 55, Iss. 2, pp. 255-259
Open Access | Times Cited: 19
Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design
Jaclyn Carberry, Mark C. Petrie, Matthew M.Y. Lee, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 4, pp. 2001-2012
Open Access | Times Cited: 8
Critical re‐evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure
Milton Packer, Stefan D. Anker, Javed Butler, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 6, pp. 1298-1312
Open Access | Times Cited: 7
Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
Hiroki Akiyama, Akihiro Nishimura, Naru Morita, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 16
Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium–glucose cotransporter 2 inhibitors
Pedro Marques, Paula Matias, Milton Packer, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 12, pp. 2191-2198
Closed Access | Times Cited: 14
Identification of three mechanistic pathways for iron-deficient heart failure
Milton Packer, Stefan D. Anker, Javed Butler, et al.
European Heart Journal (2024) Vol. 45, Iss. 26, pp. 2281-2293
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top